AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|
22.7 C
New York
Wednesday, July 29, 2026

Tag: TRI

newssourceFORcompanyinformationcontent1releasesmarket

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

SIFF Launches “AI BACKLOT”: A New Frontier in AI-Film Collaboration

SHANGHAI, June 19, 2026 /PRNewswire/ -- The 28th Shanghai International Film Festival (SIFF) has unveiled "AI BACKLOT", a pioneering initiative exploring the integration of...

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage...

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury,...

Azitra, Inc. to Present at 2026 BIO International Convention

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program

MUNICH, June 16, 2026 /PRNewswire/ -- Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology...

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

NAMI Elects New 2026-2027 Board Leadership to Advance Mental Health for All

ARLINGTON, Va., June 15, 2026 /PRNewswire/ -- The National Alliance on Mental Illness (NAMI), the nation's leading grassroots mental health organization, today announced its...

Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026

Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...

Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026

Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers